MM18 is a Swedish company launched in 2018 by Sören Nygren and Erik Wilander. It focuses on digital pathology and computer assisted analysis of tissue sections with human cancer. The aim is to obtain reproducible, correct and objective histo-pathological diagnoses without subjective microscopic examination, which may occur by surgical pathologists.  The method will shorten the process from symptoms to therapy in individuals with malignant tumours. It will also be cost effective, automatic and decrease workload.

By applying series of immuno-histochmical stains, human tissues can easily be analysed by automatic examination of digital images using tumour specific computer algoritmes. The method is patent pending since 2018.

The company is supported by ALMI and Uppsala University Innovation.

The bord consists of Erik Wilander (Chairman) and Sören Nygren  (CEO). 



Digital analysis of prostatic gland images

Globally prostatic adenocarcinoma is the most common tumor type after breast carcinoma and consequently accurate histological diagnosis of prostatic adenocarcinoma is an important issue worldwide. Prostatic adenocarcinoma is the most prevalent type of male cancer in Sweden, with over 10 000 new cases diagnosed every year. It constitutes around 30% of all male cancer cases and it occurs mainly in older men. Accordingly, 70% of the tumors are diagnosed in men 70 years of age and older. Over 2000 males die due to prostatic cancer every year and prostatic adenocarcinoma is the most common cause of death due to a malignant tumor among males in Sweden.

 In Sweden an organized screening for prostatic adenocarcinoma has not been introduced but middle aged and older men are regularly recommended screening for prostatic adenocarcinoma by performing blood sampling for analysis of PSA (Prostatic Specific Antigen).  Elevated levels of PSA indicate an increased risk for prostatic adenocarcinoma.  Males with elevated levels of PSA are recommended to attain a reception in urological surgery to obtain biopsies from the prostatic gland. These biopsies constitute the ultimate bases for the diagnosis of prostatic adenocarcinoma even if other visual methods as ultrasound and data tomography are adjuncts in that respect. In Sweden biopsies of the prostatic gland from around 20 000 men are performed every year and since 12 biopsies mostly are collected in each male around 240 000 histological sections from prostatic glands are examined each years by light microscopy performed by doctors in surgical pathology.

 At present a rapid progress in the use of digital techniques and automatic image analysis is observed in the field of medical evolution. It is likely that these techniques will play a much more dominating role as an adjunct in medical care in in the near future. (PRV application 2018).

Since may 2019, the MM18 project is supported by:

EIT Health Scandinavia
Karolinska Institutet Science Park Tomtebodavägen 23a
171 65 Solna, Sweden